全文获取类型
收费全文 | 47246篇 |
免费 | 3913篇 |
国内免费 | 104篇 |
专业分类
耳鼻咽喉 | 396篇 |
儿科学 | 1917篇 |
妇产科学 | 1345篇 |
基础医学 | 6748篇 |
口腔科学 | 973篇 |
临床医学 | 6630篇 |
内科学 | 8913篇 |
皮肤病学 | 943篇 |
神经病学 | 4871篇 |
特种医学 | 1086篇 |
外科学 | 4261篇 |
综合类 | 411篇 |
一般理论 | 67篇 |
预防医学 | 5756篇 |
眼科学 | 676篇 |
药学 | 2677篇 |
2篇 | |
中国医学 | 53篇 |
肿瘤学 | 3538篇 |
出版年
2023年 | 414篇 |
2022年 | 269篇 |
2021年 | 1038篇 |
2020年 | 975篇 |
2019年 | 1443篇 |
2018年 | 1585篇 |
2017年 | 1242篇 |
2016年 | 1340篇 |
2015年 | 1456篇 |
2014年 | 1838篇 |
2013年 | 2701篇 |
2012年 | 3776篇 |
2011年 | 3889篇 |
2010年 | 2116篇 |
2009年 | 1888篇 |
2008年 | 3145篇 |
2007年 | 3236篇 |
2006年 | 3164篇 |
2005年 | 2968篇 |
2004年 | 2886篇 |
2003年 | 2630篇 |
2002年 | 2366篇 |
2001年 | 357篇 |
2000年 | 235篇 |
1999年 | 284篇 |
1998年 | 420篇 |
1997年 | 307篇 |
1996年 | 272篇 |
1995年 | 335篇 |
1994年 | 264篇 |
1993年 | 258篇 |
1992年 | 185篇 |
1991年 | 159篇 |
1990年 | 140篇 |
1989年 | 104篇 |
1988年 | 121篇 |
1987年 | 86篇 |
1986年 | 91篇 |
1985年 | 98篇 |
1984年 | 100篇 |
1983年 | 100篇 |
1982年 | 125篇 |
1981年 | 120篇 |
1980年 | 99篇 |
1979年 | 63篇 |
1978年 | 65篇 |
1977年 | 49篇 |
1976年 | 46篇 |
1975年 | 37篇 |
1974年 | 37篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Mesny Emmanuel Barritault Marc Izquierdo Cristina Poncet Delphine d’Hombres Anne Guyotat Jacques Jouanneau Emmanuel Ameli Roxana Honnorat Jérôme Meyronet David Ducray François 《Journal of neuro-oncology》2022,157(3):511-521
Journal of Neuro-Oncology - Molecular glioblastomas (i.e. without the histological but with the molecular characteristics of IDH-wild-type glioblastoma) frequently lack contrast enhancement, which... 相似文献
2.
Simone Oerlemans PhD Fabio Efficace PhD Charalampia Kyriakou PhD MD Ana Carolina Freitas PhD MD Omar Shamieh PhD MD Carien L. Creutzberg PhD MD Jens Lehmann PhD Duska Petranovic PhD MD Eva Nagele PhD Anne Bredart PhD Dong Dong PhD Christian W. Scholz PhD MD Giovanni Caocci PhD MD Stefano Molica PhD MD Laimonas Griskevicius PhD MD Aliki Xochelli PhD MD Jacobien M. Kieffer PhD Joost A. Agelink van Rentergem PhD Waleed Alrjoub BSN Anja Mueller PhD Maria Gomes Da Silva PhD MD Filipa Alves da Costa PhD PharmD Sandra Malak PhD MD Kim Cocks PhD Lonneke V. van de Poll-Franse PhD the EORTC Quality of Life Group 《Cancer》2023,129(17):2727-2740
Background
Health-related quality of life (HRQOL) is a critical aspect to consider when making treatment decisions for patients with non-Hodgkin-lymphoma (NHL). This international study by the European Organisation for Research and Treatment of Cancer (EORTC) tested the psychometric properties of two newly developed measures for patients with high-grade (HG)- and low-grade (LG)-NHL: the EORTC QLQ-NHL-HG29 and the EORTC QLQ-NHL-LG20 to supplement the core questionnaire (EORTC QLQ-C30).Methods
Overall, 768 patients with HG-NHL (N = 423) and LG-NHL (N = 345) from 12 countries completed the QLQ-C30, QLQ-NHL-HG29/QLQ-NHL-LG20 and a debriefing questionnaire at baseline, and a subset at follow-up for either retest (N = 125/124) or responsiveness to change (RCA; N = 98/49).Results
Confirmatory factor analysis showed an acceptable to good fit of the 29 items of the QLQ-NHL-HG29 on its five scales (symptom burden [SB], neuropathy, physical condition/fatigue [PF], emotional impact [EI], and worries about health/functioning [WH]), and of the 20 items of the QLQ-NHL-LG20 on its four scales (SB, PF, EI, and WH). Completion took on average 10 minutes. Test–retest reliability, convergent validity, known-group comparisons, and RCA find satisfactory results of both measures. A total of 31%–78% of patients with HG-NHL and 22%–73% of patients with LG-NHL reported symptoms and/or worries (e.g., tingling in hands/feet, lack of energy, and worries about recurrence). Patients reporting symptoms/worries had substantially lower HRQOL compared to those without.Discussion
The use of the EORTC QLQ-NHL-HG29 and QLQ-NHL-LG20 questionnaires in clinical research and practice will provide clinically relevant data to better inform treatment decision-making.Plain language summary
- The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group developed two questionnaires.
- These questionnaires measure health-related quality of life.
- The questionnaires are for patients with high-grade or low-grade non-Hodgkin lymphoma.
- They are called the EORTC QLQ-NHL-HG29 and QLQ-NHL-LG20.
- The questionnaires are now internationally validated.
- This study demonstrates that the questionnaires are reliably and valid, which are important aspects of a questionnaire.
- The questionnaires can now be used in clinical trials and practice.
- With the information gathered from the questionnaires, patients and clinicians can better evaluate treatments and discuss the best choice for a patient.
3.
Karvandi Elika Hanrahan John Gerrard Khan Danyal Zaman Boloux Pierre-Marc Bremner Fion Cabrilo Ivan Dorward Neil Grieve Joan Jackson Sue Jimenez Glenda Serrano Inma Nowak Victoria Anne Kolias Angelos Baldeweg Stephanie E. Marcus Hani Joseph 《Pituitary》2022,25(4):673-683
Pituitary - Pituitary adenomas affect patients’ quality-of-life (QoL) across several domains, with long-term implications even following gross-total resection or disease remission. While... 相似文献
4.
Lajos Szak D vid N meth Nelli Farkas Szabolcs Kiss R ka Zsuzsa D m t r Marie Anne Engh P ter Hegyi Balint Eross r s Papp 《World journal of gastroenterology : WJG》2022,28(30):4201-4210
5.
Anna Vaczlavik Lucas Bouys Florian Violon Gaetan Giannone Anne Jouinot Roberta Armignacco Isadora P. Cavalcante Annabel Berthon Eric Letouzé Patricia Vaduva Maxime Barat Fidéline Bonnet Karine Perlemoine Christopher Ribes Mathilde Sibony Marie-Odile North Stéphanie Espiard Philippe Emy Jérôme Bertherat 《Genetics in medicine》2022,24(2):374-383
PurposeThis study aimed to investigate the genetic cause of food-dependent Cushing syndrome (FDCS) observed in patients with primary bilateral macronodular adrenal hyperplasia (PBMAH) and adrenal ectopic expression of the glucose-dependent insulinotropic polypeptide receptor. Germline ARMC5 alterations have been reported in about 25% of PBMAH index cases but are absent in patients with FDCS.MethodsA multiomics analysis of PBMAH tissues from 36 patients treated by adrenalectomy was performed (RNA sequencing, single-nucleotide variant array, methylome, miRNome, exome sequencing).ResultsThe integrative analysis revealed 3 molecular groups with different clinical features, namely G1, comprising 16 patients with ARMC5 inactivating variants; G2, comprising 6 patients with FDCS with glucose-dependent insulinotropic polypeptide receptor ectopic expression; and G3, comprising 14 patients with a less severe phenotype. Exome sequencing revealed germline truncating variants of KDM1A in 5 G2 patients, constantly associated with a somatic loss of the KDM1A wild-type allele on 1p, leading to a loss of KDM1A expression both at messenger RNA and protein levels (P = 1.2 × 10–12 and P < .01, respectively). Subsequently, KDM1A pathogenic variants were identified in 4 of 4 additional index cases with FDCS.ConclusionKDM1A inactivation explains about 90% of FDCS PBMAH. Genetic screening for ARMC5 and KDM1A can now be offered for most PBMAH operated patients and their families, opening the way to earlier diagnosis and improved management. 相似文献
6.
Alessandra Allione Clara Viberti Ilaria Cotellessa Chiara Catalano Elisabetta Casalone Giovanni Cugliari Alessia Russo Simonetta Guarrera Dario Mirabelli Carlotta Sacerdote Marco Gentile Fabian Eichelmann Matthias B. Schulze Sophia Harlid Anne Kirstine Eriksen Anne Tjønneland Martin Andersson Martijn E.T. Dollé Heleen Van Puyvelde Elisabete Weiderpass Miguel Rodriguez-Barranco Antonio Agudo Alicia K. Heath María-Dolores Chirlaque Thérèse Truong Dzevka Dragic Gianluca Severi Sabina Sieri Torkjel M. Sandanger Eva Ardanaz Paolo Vineis Giuseppe Matullo 《International journal of cancer. Journal international du cancer》2023,152(4):725-737
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer mainly caused by asbestos exposure. Specific and sensitive noninvasive biomarkers may facilitate and enhance screening programs for the early detection of cancer. We investigated DNA methylation (DNAm) profiles in MPM prediagnostic blood samples in a case-control study nested in the European Prospective Investigation into Cancer and nutrition (EPIC) cohort, aiming to characterise DNAm biomarkers associated with MPM. From the EPIC cohort, we included samples from 135 participants who developed MPM during 20 years of follow-up and from 135 matched, cancer-free, controls. For the discovery phase we selected EPIC participants who developed MPM within 5 years from enrolment (n = 36) with matched controls. We identified nine differentially methylated CpGs, selected by 10-fold cross-validation and correlation analyses: cg25755428 (MRI1), cg20389709 (KLF11), cg23870316, cg13862711 (LHX6), cg06417478 (HOOK2), cg00667948, cg01879420 (AMD1), cg25317025 (RPL17) and cg06205333 (RAP1A). Receiver operating characteristic (ROC) analysis showed that the model including baseline characteristics (age, sex and PC1wbc) along with the nine MPM-related CpGs has a better predictive value for MPM occurrence than the baseline model alone, maintaining some performance also at more than 5 years before diagnosis (area under the curve [AUC] < 5 years = 0.89; AUC 5-10 years = 0.80; AUC >10 years = 0.75; baseline AUC range = 0.63-0.67). DNAm changes as noninvasive biomarkers in prediagnostic blood samples of MPM cases were investigated for the first time. Their application can improve the identification of asbestos-exposed individuals at higher MPM risk to possibly adopt more intensive monitoring for early disease identification. 相似文献
7.
Cornelius Anna Pilger Daniel Riechardt Aline Reitemeyer Emanuel Rübsam Anne Winterhalter Sibylle Maier Anna-Karina B. 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(3):957-965
Graefe's Archive for Clinical and Experimental Ophthalmology - To compare the blood flow situation in primary open-angle glaucoma (POAG) and pseudoexfoliation glaucoma (PXG) using optical... 相似文献
8.
Neha Agnihotri Nina Cecilie
verby Elling Bere Andrew Keith Wills Anne Lise Brantster Elisabet Rudjord Hillesund 《Maternal & child nutrition》2021,17(2)
The New Nordic Diet (NND) is a potentially healthy and sustainable dietary pattern represented by locally available and traditionally consumed foods in the Northern countries. The diet has been commonly examined in adult populations, but less is known regarding its potential associations with overweight/obesity in children. We have previously developed child diet scores measuring compliance to the NND at child age 6 and 18 months and 3 and 7 years. In this study, we aimed to describe child and maternal characteristics and assess potential associations between the age‐specific diet scores and child overweight at 8 years. This study is based on the Norwegian Mother, Father and Child Cohort Study (MoBa), including 14,989 mother–child pairs and uses data from the Medical Birth Registry of Norway (MBRN). The scores measured NND compliance as a total score and categorized into low, medium and high NND compliance at each age point. Using logistic regression models, we investigated the association between each age‐specific score and the odds of overweight at 8 years. In crude analyses, adherence to the NND at 6 months was inversely associated with odds of overweight at 8 years in the continuous score (odds ratio = 0.95, 95% CI [0.91, 0.98]) and when comparing high versus low NND adherence (odds ratio = 0.81, 95% CI [0.70, 0.94]). The association was almost entirely attenuated in the adjusted models. In conclusion, child NND adherence up to 7 years of age was not associated with odds of overweight at 8 years in adjusted analyses. 相似文献
9.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
10.